What question did this study set out to answer?

To estimate nationwide SARS-CoV-2 antibody seroprevalence across demographic groups and jurisdictions using commercial laboratory residual sera and assess temporal trends over time.

November 25, 2020JAMA Internal MedicineOpen Access

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

View Full Paper

Ask AI

Bookmark

Authors

KBKristina L. BajemaOregon Health & Science University RWRyan E. WiegandCenters for Disease Control and Prevention KCKendra M. CuffeCenters for Disease Control and Prevention

Discussion

Member takes

Overview

Repeated cross-sectional study reveals SARS-CoV-2 seroprevalence remained below 10% across most jurisdictions, highlighting widespread population susceptibility through late 2020.

Key Points

To estimate nationwide SARS-CoV-2 antibody seroprevalence across demographic groups and jurisdictions using commercial laboratory residual sera and assess temporal trends over time.
Conducted a repeated cross-sectional study across all 50 states, the District of Columbia, and Puerto Rico using N = 177,919 residual serum samples submitted for routine clinical testing across four biweekly periods between July 27 and September 24, 2020.
Tested specimens for SARS-CoV-2 antibodies using 1 of 3 commercial chemiluminescent immunoassays.
Standardized seroprevalence estimates to local population profiles and urbanicity using iterative poststratification across age groups, sexes, and metropolitan versus nonmetropolitan areas.
Jurisdiction-level seroprevalence across the four collection periods ranged from less than 1% to 23%.
Seroprevalence remained below 10% in 42 of the 49 jurisdictions that had sufficient samples to evaluate across all collection rounds.
Seroprevalence shifts between the first and fourth collection windows were under 7 percentage points across all sites, while showing substantial variation by sex, age, and urbanicity.

Cite This Study

Bajema et al. (2020) studied this question.

synapsesocial.com/papers/6aaa466a3581ab7f190839e4 https://doi.org/10.1001/jamainternmed.2020.7976

View Full Paper

Ask AI

Bookmark

November 25, 2020JAMA Internal MedicineOpen Access

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

View Full Paper

Ask AI

Bookmark

Authors

KBKristina L. BajemaOregon Health & Science University RWRyan E. WiegandCenters for Disease Control and Prevention KCKendra M. CuffeCenters for Disease Control and Prevention

Discussion

Member takes

Overview

Repeated cross-sectional study reveals SARS-CoV-2 seroprevalence remained below 10% across most jurisdictions, highlighting widespread population susceptibility through late 2020.

Key Points

To estimate nationwide SARS-CoV-2 antibody seroprevalence across demographic groups and jurisdictions using commercial laboratory residual sera and assess temporal trends over time.
Conducted a repeated cross-sectional study across all 50 states, the District of Columbia, and Puerto Rico using N = 177,919 residual serum samples submitted for routine clinical testing across four biweekly periods between July 27 and September 24, 2020.
Tested specimens for SARS-CoV-2 antibodies using 1 of 3 commercial chemiluminescent immunoassays.
Standardized seroprevalence estimates to local population profiles and urbanicity using iterative poststratification across age groups, sexes, and metropolitan versus nonmetropolitan areas.
Jurisdiction-level seroprevalence across the four collection periods ranged from less than 1% to 23%.
Seroprevalence remained below 10% in 42 of the 49 jurisdictions that had sufficient samples to evaluate across all collection rounds.
Seroprevalence shifts between the first and fourth collection windows were under 7 percentage points across all sites, while showing substantial variation by sex, age, and urbanicity.

Cite This Study

Bajema et al. (2020) studied this question.

synapsesocial.com/papers/6aaa466a3581ab7f190839e4 https://doi.org/10.1001/jamainternmed.2020.7976

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark